DEA’s Latest Policy Change Another Burden on Cannabis Research

CANNABIS CULTURE –  Dr. John Streicher of the University of Arizona says the DEA’s new regulations offer no help to researchers — and he’s not the only one.

“From my point of view it makes no difference at all,” Streicher says under the new rules he will still need to file for a Schedule I license with the DEA, as he did under the old regulations. 

Streicher’s research focuses on pain management, often with opioids and requires a Schedule II license. With routine inspections, Streicher can research opioids: codeine, morphine, and oxycodone with little oversight. 

The security requirements for storing Schedule I substances in the lab is far higher. Streicher says that isn’t the only difficulty, “It’s the additional burden of all the details.” 

Researchers need to provide exact plans in their application for everything they want to do. “A lot of things change in research,” he says. “You make one discovery and that may lead to five new directions that you want to go in.” Streicher says de-scheduling cannabis is the only route to help research. 

Dr. Josh Kaplan of Western Washington University says his research focuses on CBD because of the restrictions on THC. “There are companies right

Read More Here…

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Bud Digest[otw_is sidebar=otw-sidebar-8]

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top